Leerink Partnrs Has Negative Outlook for Insulet Q4 Earnings

Insulet Co. (NASDAQ:PODD) – Equities researchers at Leerink Partnrs reduced their Q4 2024 EPS estimates for shares of Insulet in a research note issued on Monday, November 25th. Leerink Partnrs analyst M. Kratky now forecasts that the medical instruments supplier will earn $0.97 per share for the quarter, down from their prior forecast of $0.99. The consensus estimate for Insulet’s current full-year earnings is $3.22 per share. Leerink Partnrs also issued estimates for Insulet’s Q2 2025 earnings at $0.87 EPS, Q3 2025 earnings at $1.14 EPS, Q4 2025 earnings at $1.20 EPS, FY2025 earnings at $3.89 EPS, FY2026 earnings at $5.21 EPS and FY2027 earnings at $6.49 EPS.

Several other equities analysts have also weighed in on PODD. Canaccord Genuity Group raised their price objective on shares of Insulet from $236.00 to $269.00 and gave the company a “buy” rating in a research report on Wednesday, September 25th. Barclays raised their price objective on shares of Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research report on Monday, November 11th. Sanford C. Bernstein started coverage on shares of Insulet in a research report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 price objective for the company. Piper Sandler raised their price objective on shares of Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a research report on Tuesday, September 17th. Finally, Morgan Stanley raised their price objective on shares of Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research report on Monday, November 11th. Three investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $253.27.

Insulet Stock Performance

Shares of PODD opened at $266.42 on Tuesday. The firm has a 50-day moving average price of $241.97 and a 200 day moving average price of $211.65. The firm has a market capitalization of $18.69 billion, a PE ratio of 45.62, a P/E/G ratio of 4.02 and a beta of 1.22. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. Insulet has a 52-week low of $160.19 and a 52-week high of $279.40.

Institutional Investors Weigh In On Insulet

Large investors have recently made changes to their positions in the stock. Blue Trust Inc. boosted its holdings in shares of Insulet by 84.1% in the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 58 shares during the last quarter. Venturi Wealth Management LLC raised its stake in Insulet by 633.3% in the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 133 shares during the period. International Assets Investment Management LLC bought a new stake in Insulet in the 2nd quarter valued at $32,000. UMB Bank n.a. raised its stake in Insulet by 81.0% in the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after acquiring an additional 81 shares during the period. Finally, TD Private Client Wealth LLC raised its stake in Insulet by 32.6% in the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock valued at $53,000 after acquiring an additional 56 shares during the period.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.